Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)
Worldwide, cancer is a major public health issue and accurate diagnosis, staging and follow-up is essential for optimal management. PET-CT imaging has a significant role in the staging of disease and assessment of treatment response.
KeywordsClinical Target Volume Gross Tumour Volume Major Public Health Issue Dose Painting Biological Target Volume
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 1.Cancer Research UK. What radiotherapy is. 2014. http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/radiotherapy/about/what-radiotherapy-is. Accessed 9 Jan 2015.
- 6.Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22(21):4357–68.CrossRefPubMedGoogle Scholar
- 15.Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.Google Scholar
- 18.Cheebsumon P, Boellaard R, de Ruysscher D, et al. Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology. Eur J Nucl Med Mol Imaging. 2012;2(1):56.Google Scholar
© Springer International Publishing Switzerland 2017